Nautilus Biotechnology (NAUT) Net Cash Flow (2020 - 2026)

Nautilus Biotechnology has disclosed Net Cash Flow across 7 years of filings, most recently posting $2.2 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $2.2 million, down 59.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$18.6 million (down 347.86% YoY), and the FY2025 annual result was -$15.3 million, down 284.97% from the prior year.
• Net Cash Flow came in at $2.2 million for Q1 2026 at Nautilus Biotechnology, up from -$11.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $23.2 million in Q4 2024 to a low of -$74.3 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$844000.0 (2024), against an average of -$10.0 million.
• Across the five-year window, Net Cash Flow slumped 1613.38% in 2024 and surged 244.43% in 2025, its largest moves.
• Nautilus Biotechnology's Net Cash Flow stood at -$74.3 million in 2022, then rose by 26.37% to -$54.7 million in 2023, then jumped by 142.48% to $23.2 million in 2024, then plunged by 149.43% to -$11.5 million in 2025, then surged by 119.48% to $2.2 million in 2026.
• The last three Net Cash Flow figures came in at $2.2 million (Q1 2026), -$11.5 million (Q4 2025), and -$10.6 million (Q3 2025), per Business Quant data.